The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation
Abstract
Delivery of nucleic acids with positively charged lipid nanoparticles ((+)NPs) is widely used as research reagents and potentially for therapeutics due to their ability to deliver nucleic acids into the cell cytoplasm. However, in most reports little attention has been made to their toxic effects. In the present study, we performed comprehensive analyses of the potential toxicity associated with (+)NPs. Mice treated with (+)NPs showed increased liver enzyme release and body weight loss compared to mice treated with neutral or negatively charged NPs ((-)NPs), suggesting hepatotoxicity. Intravenous administration of (+)NPs induced interferon type I response and elevated mRNA levels of interferon responsive genes 15-25-fold higher than neutral and (-)NPs in different subsets of leukocytes. Moreover, treatment with (+)NPs provoked a dramatic pro-inflammatory response by inducing Th1 cytokines expression (IL-2, IFN gamma and TNF alpha) 10-75-fold higher than treatment with control particles. Finally, we showed that activation of TLR4 might serve as the underlying mechanism for induction of an immune response when (+)NPs are used. These results suggest that a careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cationic and ionizable lipids have also been reported to stimulate the secretion of pro-inflammatory cytokines and reactive oxygen species170–173.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“Although the immunogenicity of these lipids has not yet been fully understood, complement system and Toll-like receptors may participate in innate immune activation170,173–175.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
In the citing paper
“In vivo application of lipid nanoparticles has been reported to induce liver and lung injuries in rodents170,173, which may be attributed to the cytotoxicity of the materials and the induction of”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [170]
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H., Maraganore, J. M., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,223
NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials
Singh, N., Manshian, B. B., Jenkins, G. J. S., Griffiths, S. M., Williams, P. M., Maffeïs, T. G. G., Wright, C. J., & Doak, S. H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.04.009 · Cited by 1,212
LPS, TLR4 and infectious disease diversity
Miller, S., Ernst, R. K., & Bader, M. W. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1068 · Cited by 1,059
Williams, D. F. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.027 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Cited by
Sorted by citations
Items 501–544 of 544
Lipid-Based Nanomaterials in Cancer Treatment and Diagnosis
Obeid, M. A., Qaraghuli, M. M. A., Ruano, M., Sangboonruang, S., Alsaadi, M., Tragoolpua, Y., & Ferro, V. A. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815051278122010005
Navigating Uncharted Waters: Could Certain COVID-19 Vaccines Promote Malignancy?Preprint
Angues, R. V., & Bustos, Y. P. (2022) · doi:10.22541/au.166358581.18921295/v1
Wang, Y., Wang, M., Lin, N., Ni, C., & Xu, Y. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00078
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Walther, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2032
Sun, J. W., Thomas, J. S., Monkovic, J., Gibson, H., Nagapurkar, A., Frezzo, J. A., Katyal, P., Punia, K., Mahmoudinobar, F., Renfrew, P. D., et al. (2024) · Journal of Peptide Science · doi:10.1002/psc.3594
Jung, H. Y., Kim, T. H., Hadinoto, K., & Park, J.-W. (2024) · Tenside Surfactants Detergents · doi:10.1515/tsd-2024-2610
Duangchan, K., Limjunyawong, N., Rodponthukwaji, K., Ittiudomrak, T., Thaweesuvannasak, M., Kunwong, N., Metheetrairut, C., Sirivatanauksorn, V., Sirivatanauksorn, Y., Kositamongkol, P., et al. (2024) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.4c00061
“These observations are consistent with Kedmi et al. (2010), who also observed a decrease in the charge of nanoparticles after encapsulation of siRNA due to its negative charge.”
Shaikh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7292-6_27
Huynh, K. T., Armstrong, R. J., Speese, S. D., & Schutt, C. E. (2025) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202400187
The Impact of Green Nanomaterials on the Agri-food Industry
Félix-Portillo, M., Carrillo-López, L. M., Garcia-Galicia, I. A., Huerta‐Jimenez, M., Suleman, R., & Alarcon-Rojo, A. D. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677313-00033
Harnessing Argonaute 2 as an innovative delivery system for siRNA in glioblastoma treatment
Rinaldi, A., Kluczka, E., Nazir, M. L. F., Barbotin, M., Roy, C., Basset, L., Avril, S., Anthiya, S., Tosi, G., Jérôme, C., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107459
Yadava, S. K., Tripathi, A., Kabilan, M., Champion, J. A., & Cicerone, M. T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114312 · Cited by 1
Nanoparticles and female reproductive toxicity: a review
Kumar, C., & Sharma, R. K. (2025) · BULGARIAN JOURNAL OF VETERINARY MEDICINE · doi:10.15547/bjvm.2023-0130
“…and triggered the release of IL-1β in THP-1 cells and BMDCs. Similarly, alteration of NPs surface charge differently impacts the immune response: Kedmi et al. (2010) found out that mice treated with (+) NPs showed increased hepatotoxicity and pro-inflammatory response due to increased…”
Liposomes mediated anticancer drug delivery approaches for treatment of skin cancer
Aktürk, Ö. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33548-8.01007-7
Hartmann, U. (2025) · De Gruyter eBooks · doi:10.1515/9783486855449-003
Nanomedicine for Conjugated Therapy and Diagnosis in Cancer Treatment
Sahoo, P., Das, M., Adhikari, S., Mukherjee, A., & Ghosh, C. K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813123125010009
Pharmaceutical Formulations Using Polymer Nanocomposites
Ben, K. B., Amule, A. A., Deogratias, D., Odongo, D., Muganga, G., Desire, K. C. K., Mwandah, D. C., Josephine, N., Sesaazi, D. C., Paulo, N., et al. (2026) · Springer eBooks · doi:10.1007/978-3-032-00365-2_14
Patra, S., Kar, S., Chakraborty, A., Rakshit, S., & Dey, J. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c05004
Toward precision immunotherapy: In vivo gene editing of T, NK, and myeloid cells
Nguyen, K. H., Das, S., & Matosevic, S. (2026) · Med · doi:10.1016/j.medj.2025.100992 · Cited by 1
Ye, Z., Jin, X., Koekman, A. C., van Steenbergen, M. J., Liu, Y., Xing, Z., Seinen, C. W., Khodaei, A., Mastrobattista, E., Sluijter, J. P. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.25.707929
“…and reported that DOTAP-containing positively charged nanoparticles ( ∼ 100 nm; ζ ≈ +54 mV) induced body-weight loss and elevated serum liver enzymes after intravenous dosing, accompanied by strong induction of Th1 cytokines and type I interferon–responsive genes in leukocyte populations (52).”
Roberto, G. T. E. C., Masiero, J. F., Stephano, M. A., & Bou‐Chacra, N. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108267
Evaluation of the safety and drug delivery efficacy of carbon dots in in vitro and in vivo models
Fan, J. (2018) · doi:10.70675/1c7fc388ze650z4420z9c0dz7de38470b8e4
“This actin-driven endocytic process is not directly coordinated by the presence of cargo, but can be induced when the growth factor signaling pathway is activated (Kerr and Teasdale, 2009).”
BackgroundVectorisation d'ARN par voie orale et parentérale
Stalder, T. (2024) · theses.fr (ABES) · doi:10.70675/d509592fzbb96z4f17zb286z5040de22fd65
Novel Nanotechnological Approaches for Glioblastoma Targeting
Rinaldi, A. (2024) · theses.fr (ABES) · doi:10.70675/f2906991zf1b3z4908z89b3z3540c81fe044
Zhang, M., Taravatfard, A. Z., Aghaamoo, M., & Lee, A. P. (2026) · Lab on a Chip · doi:10.1039/d5lc00941c
Graham, J. P., Arteaga, A., Moghaddam, A. S., Spiller, K. L., Laverty, D. J., & Gonzalez‐Fernandez, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728905 · Cited by 1
“28,29 Efforts must be taken to minimize these unintended transcriptomic effects for the accurate interpretation of gene editing outcomes and designing reproduceable strategies.”
Zhu, G., Li, D., Zhang, H., Wang, J., Li, X., Zeng, L., Zhang, L., & Yu, L. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s598118
“145 Furthermore, the targeting of LNPs still needs improvement.”
Consolidated and next-generation models in DDS nanotoxicology assessment: Where do we stand
D’Intino, E., Stacchini, F. R., Fabiano, M. G., Marianecci, C., & Carafa, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108598
Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies
Goemaere, I., Velder, M. D., Smedt, S. C. D., Lentacker, I., Vos, W. H. D., & Braeckmans, K. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115924
Jugniot, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119213
Meng, F., & Goda, T. (2026) · Langmuir · doi:10.1021/acs.langmuir.6c03381
Macromolecular Design Principles for Polymer‐Lipid Hybrid Nanoparticles in RNA Delivery
Shao, B., Chen, M., & Liu, S. (2026) · Macromolecular Rapid Communications · doi:10.1002/marc.70402 · Cited by 1
“After endocytosis, protonation in the acidified endosomal compartment restores electrostatic and membrane activity, facilitating interactions with endosomal membranes [ 24–26 ].”
Lu, L., Qiu, Y., Wu, J., Dou, W., Yang, J., & Zhang, B. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091108
“Permanently cationic lipids facilitate RNA association and cellular entry, but positively charged lipid nanoparticles have been associated with liver injury and inflammatory cytokine production [73].”
Lu, Y., Qu, T., Zang, C., Cui, X., Su, C., Liu, X., Song, Y., & Deng, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115413
Liposomal nanoparticle mediated gene modulation for the treatment of melanoma in murine models
Yadav, P., Kelly, P. J., Mandal, S. K., Williams, M. L., Tang, B., McWatters, A., & Sheth, R. A. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2738804
The tRNA‐Modification Geranyl‐2‐Thiouridine Enables RNA‐Lipid Association
Singer, J., Halter, K., Chan, C., & Carell, T. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.9140489
Die tRNA‐Modifikation Geranyl‐2‐thiouridin ermöglicht eine RNA‐Lipid Assoziation
Singer, J., Halter, K., Chan, C., & Carell, T. (2026) · Angewandte Chemie · doi:10.1002/ange.9140489
Ahn, J.-H., Lee, N.-Y., Bae, H.-J., Kim, J., Kwak, J., Roh, G., Bae, S., Lee, J., Nam, J.-H., Kim, J.-E., et al. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag134
Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors
Zhao, N., Zhang, Y., Qian, C., 张华巍, & Wang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189732
Supachettapun, C., Jayeoye, T. J., Wongsam, P., Okajima, M. K., Kaneko, T., Khanchaitit, P., Sansanaphongpricha, K., Matsumura, K., & Muangsin, N. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00970k
Ullah, A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109045
Bespalov, M., Shirokova, L., Mazunina, E. P., Kozlova, S. R., Bykonia, E. N., Vasileva, O., Konovalova, S. P., Venediktova, Y. B., Vorontsova, M. S., Gushchin, V., et al. (2026) · Pathophysiology · doi:10.3390/pathophysiology33040081
Metadata
- Authors
- Kedmi, R., Ben-Arie, N., & Peer, D.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Peer, Dan
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 31
- Issue
- 26
- Pages
- 6867-6875
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2126020016
- Cited by
- 546
- References
- 52
- Citations by year
- 2026: 39 · 2025: 60 · 2024: 67 · 2023: 52 · 2022: 54 · 2021: 33 · 2020: 31 · 2019: 29 · 2018: 26 · 2017: 31 · 2016: 14 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 25
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- nanoparticle toxicity, TLR4, hepatotoxicity, inflammatory cytokines, Th1 response, nucleic acid delivery, nanotherapeutics, immune activation
- MeSH terms
- Animals, Immunity, Inflammation, Lipids, Mice, Inbred C57BL, Particle Size, Surface Properties, RNA, Small Interfering, Toll-Like Receptor 4, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
